Vericel (VCEL) amends bylaws to reflect new Burlington, MA global headquarters
Vericel Corporation (VCEL) has amended its corporate bylaws to reflect its new global headquarters located at 25 Blue Sky Drive, Burlington, Massachusetts 01803. The amendment was approved by the Board of Directors and became effective on May 18, 2026. This change ensures that the company's official corporate records align with its updated principal executive office address.
Vericel Corporation $VCEL Stock Position Reduced by Truist Financial Corp
Truist Financial Corp reduced its stake in Vericel Corporation ($VCEL) by 59.9% in the fourth quarter, selling 37,035 shares and retaining 24,763 shares valued at approximately $892,000. Despite this reduction, other institutional investors increased their positions, and Vericel's recent quarterly results exceeded expectations with EPS of -$0.12 and revenue of $68.43 million. Analyst sentiment for VCEL remains mixed but generally constructive, with a "Moderate Buy" consensus rating and an average price target of $55.40.
Vericel (VCEL) director McLaughlin exercises options and sells 7,000 shares
Vericel Corp director Kevin F. McLaughlin exercised stock options to acquire 7,000 shares and subsequently sold all 7,000 shares in open-market transactions on May 13, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 12, 2025. After these transactions, McLaughlin directly held 18,300 shares of Vericel common stock.
Vericel director Paul Wotton sells $327,425 in company stock By Investing.com
Paul K. Wotton, a director at Vericel Corp, sold 10,000 shares of the company's common stock for a total of $327,425 on May 11, 2026. The stock traded between $32.64 and $33.05 per share, and following the sale, Wotton directly holds 18,802 shares. Despite a recent decline of over 10% in the past week, InvestingPro analysis indicates that the $1.68 billion biotech company is undervalued based on its Fair Value assessment.
Vericel director Paul Wotton sells $327,425 in company stock
Vericel director Paul Wotton sold 10,000 shares of Vericel Corp (NASDAQ:VCEL) common stock for $327,425 on May 11, 2026, with the shares trading between $32.64 and $33.05. Despite this sale and a recent stock decline, InvestingPro suggests the company is undervalued. Vericel also reported strong Q1 2026 financial results, exceeding revenue and EPS expectations.
Director Paul K. Wotton sells 10,000 Vericel (VCEL) shares around $33
Vericel director Paul K. Wotton sold a total of 10,000 shares of common stock in open-market transactions on May 11, 2026. The sales were executed in two separate transactions at prices of $32.64 and $33.05 per share, amounting to a net sale of $327,425. Following these transactions, Wotton's direct holdings in Vericel Common Stock total 26,302 shares.
Issuer (NASDAQ: VCEL) notifies sale of 7,000 common shares
Vericel Corporation (NASDAQ: VCEL) has filed a Form 144 notice to sell 7,000 shares of common stock through Fidelity Brokerage Services LLC on May 13, 2026. These shares originate from two option grants issued in 2017 and 2018, each for 3,500 shares. The filing is a regulatory intent to sell and does not provide details on sale proceeds or full seller identity.
[144] Vericel Corp SEC Filing
This article details a Form 144 SEC filing by Vericel Corp (VCEL) regarding a proposed sale of securities. An individual is selling 10,000 shares of common stock, valued at $327,425.00, acquired on May 11, 2021, through a stock option exercise. The sale is scheduled for May 11, 2026, on NASDAQ, and Oppenheimer & Co Inc is handling the transaction.
Vericel Corporation (NASDAQ:VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (NASDAQ:VCEL) reported a strong Q1 2026, with total revenue exceeding $68 million, a 30% increase year-over-year, driven by substantial growth in both MACI and the Burn Care business. The company raised its full-year 2026 revenue guidance by $10 million to a range of $326 million to $336 million, citing strong Q1 performance, continued business momentum, and expected NexoBrid BARDA procurement revenue. Discussions also covered the successful expansion of the MACI sales force, the growing adoption and positive early data for MACI Arthro, and the long-term potential of the BARDA award for NexoBrid, while dismissing competitive threats from other cartilage repair products.
Insider Sell: Mara Joseph Anthony Jr Sells 5,000 Shares of Veric
Mara Joseph Anthony Jr, CFO of Vericel Corp (VCEL), recently sold 5,000 shares, reducing his holdings to 21,009 shares. Over the past year, there have been 17 insider sells and no insider buys at Vericel. The stock, trading at $40.50, is considered significantly undervalued against its GF Value of $50.42, despite a higher-than-industry price-earnings ratio.
Vericel (NASDAQ: VCEL) accounting chief sells 4,855 shares
Vericel's Principal Accounting Officer, Jonathan Siegal, sold a total of 4,855 shares of company common stock in open-market transactions on May 6 and May 7, 2026. These sales, valued at $188,045, were pre-arranged under a Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Siegal directly holds 1,118 shares of Vericel common stock.
Vericel (VCEL) CFO 10b5-1 sale leaves 21,009 shares held
Vericel Corp's CFO, Mara Joseph Anthony Jr, completed an automatic open-market sale of 5,000 shares of common stock at $40.50 per share on May 7, 2026. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 2, 2025. Following the sale, the CFO retains 21,009 shares, including those acquired through the company’s 2015 Employee Stock Purchase Plan.
Vericel Corp reports results for the quarter ended March 31 - Earnings Summary
Vericel Corp has released its earnings summary for the quarter that ended on March 31. The report contains the financial results for the specified period. This news was originally reported by Reuters and published on TradingView.
Vericel Corp 1Q 2026: Revenue $68.43M, EPS ($0.12) — 10-Q Summary
Vericel Corp (VCEL) reported its first-quarter 2026 results, showing revenue of $68.43 million, a 30.1% increase year-over-year from $52.6 million. The company narrowed its net loss to $6.3 million, or diluted EPS of ($0.12), significantly improving from a net loss of $11.25 million, or diluted EPS of ($0.23), in the prior year. Growth was mainly driven by strong sales of MACI and Epicel, alongside progress in MACI Arthro commercialization and clinical pipeline developments.
[144] Vericel Corp SEC Filing
Vericel Corporation has filed a Form 144 notice proposing the sale of 5,000 shares of common stock, valued at $202,500.00, through Fidelity Brokerage Services LLC. The filing, dated May 7, 2026, details that these shares stem from restricted stock vesting events occurring in February 2025. This regulatory document provides transparency into potential insider sales.
BARDA burns contract backs NexoBrid growth at Vericel (VCEL)
Vericel Corporation (VCEL) reported strong first-quarter 2026 results with revenue up 30% to $68.4 million, driven by growth in MACI and Epicel sales, while net loss narrowed to $6.3 million. The company reinforced its financial position with $210.6 million in cash and investments and no outstanding debt on its $150 million revolving credit facility. A significant development was a ten-year, up to $196.9 million agreement with BARDA for NexoBrid procurement and development, aiming to expand its burn care franchise.
Vericel Reports Q1 2026: Revenue Up 30% to $68.4M, Adjusted EBITDA $9.6M
Vericel reported strong first-quarter 2026 results, with total net revenue increasing 30% to $68.4 million and adjusted EBITDA reaching $9.6 million. The company's gross margin was 72%, and it recorded a net loss of $6.3 million, alongside a healthy free cash flow of $15.1 million. Vericel raised its full-year 2026 revenue guidance to $326–$336 million, driven by significant growth in both MACI and Burn Care segments and FDA approval for MACI commercial manufacturing at its new facility.
Burn care sales surge 91% as Vericel lifts 2026 revenue target
Vericel (NASDAQ: VCEL) announced strong first-quarter 2026 financial results, with total revenue increasing 30% to $68.4 million and burn care revenue surging 91% to $12.0 million. The company raised its full-year 2026 revenue guidance to between $326 million and $336 million, driven by robust performance across its MACI and Burn Care franchises. Despite a net loss, adjusted EBITDA saw a significant 195% increase, demonstrating improved profitability and cash generation.
Vericel (NASDAQ: VCEL) lifts 2026 outlook after 30% Q1 revenue gain
Vericel Corporation reported a strong first quarter for 2026, with total revenue increasing by 30% to $68.4 million, driven by significant growth in both MACI and Burn Care segments. The company also improved its profitability metrics, narrowing its net loss and substantially increasing adjusted EBITDA and free cash flow. Consequently, Vericel raised its full-year 2026 revenue guidance to a range of $326 million to $336 million, reflecting continued positive momentum.
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Corporation (VCEL) reported a Q1 loss of $0.12 per share, which beat the Zacks Consensus Estimate of a $0.15 loss, representing a 17.24% earnings surprise. The company also surpassed revenue estimates, posting $68.43 million against a consensus of $63.8 million. Despite underperforming the S&P 500 year-to-date, Vericel holds a Zacks Rank #2 (Buy) due to favorable estimate revisions.
VCEL (NASDAQ: VCEL) Form 144 lists 3,433 shares valued $130,454; vesting noted
Vericel (VCEL) filed a Form 144 notice for a proposed sale of 3,433 common shares, valued at $130,454, by Fidelity Brokerage Services LLC. The filing also detailed restricted stock vesting events for a total of 3,433 shares occurring in February 2026. This notice indicates proposed dispositions and compensation-related vesting, but does not confirm sale execution or proceeds.
Vericel faces earnings test as Q1 loss looms after FDA approval By Investing.com
Vericel is expected to report a Q1 earnings loss despite recent FDA approval for its manufacturing facility and growth in the cell therapy market. Analysts anticipate an adjusted loss of $0.15 per share on revenue of $63.7 million, questioning if demand for its MACI cartilage repair therapy can sustain momentum. Investors will closely watch commentary on the new manufacturing facility's ramp-up and the company's full-year guidance for 2026.
Vericel (VCEL) director reports RSU vesting and new stock option awards
Vericel Corp director Robert L. Zerbe, M.D. reported equity compensation activity, not open-market trades. On April 29, 2026, 3,200 Restricted Stock Units (RSUs) vested and were exercised, increasing his direct common stock holdings to 32,995 shares. Simultaneously, he received new awards: 3,200 RSUs vesting on April 29, 2027, or the next Annual Meeting, and stock options for 8,000 shares at an exercise price of $33.43, vesting monthly over one year.
Vericel (VCEL) director defers RSUs and receives new option grant
Vericel Corp director Lisa Wright reported equity compensation, including exercising 3,200 Restricted Stock Units (RSUs) into Phantom Stock and deferring them under the company's Deferred Compensation Plan. She also received a new grant of 3,200 RSUs and stock options for 8,000 shares at an exercise price of $33.43. The filing indicates no open-market buying or selling of shares by Wright, who now holds 15,851 common shares.
Vericel (VCEL) director receives new RSU and stock option grants
Vericel Corp director Kevin F. McLaughlin reported compensation-related equity activity, converting 3,200 previously granted Restricted Stock Units (RSUs) into common stock, bringing his total direct holdings to 18,300 shares. Concurrently, he received new grants of 3,200 RSUs and stock options for 8,000 shares with an exercise price of $33.43. The new RSUs vest by April 29, 2027, or the next Annual Meeting, while the options vest monthly over one year, both contingent on continued service.
Vericel (NASDAQ: VCEL) director logs RSU conversion and new 8,000-share option grant
Vericel Corporation director Paul K. Wotton reported equity compensation activities, including the conversion of 3,200 Restricted Stock Units (RSUs) into common stock and a new grant of 3,200 RSUs and 8,000 stock options. The stock options have an exercise price of $33.43 per share and vest over one year, while the RSUs vest by April 29, 2027, or the next annual stockholders meeting. Following these transactions, Wotton's direct holdings increased to 28,802 shares of common stock.
Vericel (NASDAQ: VCEL) director awarded RSUs and 8,000 stock options
Vericel director Heidi Hagen reported equity compensation activity, including the exercise of 3,200 Restricted Stock Units (RSUs) and the grant of an additional 3,200 RSUs and 8,000 stock options. Following these transactions, Hagen directly holds 35,050 shares of Vericel common stock. These actions reflect routine compensation rather than open-market trading.
Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor
Vericel (NASDAQ:VCEL) held its 2026 annual shareholder meeting where seven directors were elected to one-year terms. Shareholders also approved the advisory resolution on executive compensation and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Approximately 95% of outstanding shares were represented at the virtual meeting, and no additional shareholder proposals or questions were submitted.
Vericel (VCEL) director gains RSUs, options and more common shares
Vericel Corp director Alan L. Rubino increased his equity-based holdings through the vesting of 3,200 Restricted Stock Units (RSUs) into common stock, bringing his total direct common stock holdings to 64,194 shares. He also received a new grant of 3,200 RSUs and stock options for 8,000 shares with an exercise price of $33.43, both set to vest over time. These transactions represent routine equity compensation rather than open-market purchases or sales.
Conestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCEL
Conestoga Capital Advisors LLC increased its stake in Vericel Corporation by 3.6% in the fourth quarter, purchasing an additional 79,278 shares to bring its total holding to 2,254,562 shares valued at approximately $81.19 million. Several other institutional investors also adjusted their holdings in Vericel. The company reported strong Q4 earnings, meeting analyst estimates with $0.45 EPS and exceeding revenue expectations with $92.92 million, a 23.3% year-over-year increase.
Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor
Vericel (NASDAQ: VCEL) held its 2026 annual meeting where shareholders re-elected seven directors, approved the advisory "say-on-pay" proposal for executive compensation, and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The meeting, which had about 95% of outstanding shares represented, concluded without any additional shareholder questions or proposals.
Vanguard buys/holds 2.60M Vericel shares — Vericel (NASDAQ: VCEL)
Vanguard Capital Management has disclosed a 5.11% beneficial ownership stake in Vericel (NASDAQ: VCEL), amounting to 2,603,128 shares of common stock. This is reported via a Schedule 13G SEC filing, indicating Vanguard holds these shares for investment purposes across various affiliated funds and client accounts. The filing specifies Vanguard's sole voting power over 372,372 shares and sole dispositive power over all 2,603,128 shares.
Vericel (VCEL) Expected to Announce Earnings on Thursday
Vericel (NASDAQ:VCEL) is slated to release its Q1 2026 earnings before market open on Thursday, May 7th. Analysts anticipate the biotechnology company will report ($0.15) EPS and revenues of $63.697 million. The stock is currently trading down by approximately 6.2%, though Wall Street analysts generally hold a "Moderate Buy" rating with a mean target price of $55.40.
Vericel sets May 7 earnings call, with webcast replay through 2027
Vericel Corporation (NASDAQ: VCEL) announced it will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss the results and business highlights, with a replay available until May 7, 2027. The company's recent achievements include FDA approval for MACI manufacturing, a significant BARDA contract for NexoBrid, and strong 2025 financial results.
Truist Cuts Price Target on Vericel to $42 From $48, Keeps Buy Rating
Truist has lowered its price target for Vericel (VCEL) to $42 from $48, while maintaining a Buy rating on the stock. This adjustment comes despite recent positive news for Vericel, including a significant BARDA contract and FDA approval for a new manufacturing facility. The company specializes in advanced therapies for sports medicine and severe burn care, with products like MACI, Epicel, and NexoBrid.
Vericel Corporation (VCEL) secures FDA approval for commercial manufacturing of MACI
Vericel Corporation (VCEL) has received FDA approval for the commercial manufacturing of its MACI product. This approval signifies a significant regulatory milestone for the company, indicating that its manufacturing processes meet the required standards for bringing MACI to market. This development could potentially enhance Vericel's ability to meet product demand and expand its market presence.
Critical Limb Ischemia Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Baxter, Ixaka, Hemostemix Inc., Caladrius Biosciences, Vericel Corporation, Helixmith, Lifecells, LLC
The Critical Limb Ischemia (CLI) market was valued at approximately USD 1,845 million in 2023 and is projected to grow significantly by 2034, driven by increasing prevalence and a rich pipeline of emerging therapies. The United States held the largest market share in 2023, while Germany led the European market. Key companies like Boston Scientific, Ixaka, and Hemostemix are developing new treatments, including drug-coated balloons and cell therapies, to address this severe peripheral artery disease.
Q3 2025 Vericel Corp Earnings Call Transcript
Vericel Corp (VCEL) reported record third-quarter 2025 revenue of $67.5 million, exceeding guidance, with GAAP net income over $5 million and an adjusted EBITDA margin of 25%. This strong performance was driven by a 25% increase in Macy revenue, including the successful launch of Macy Arthro. The company also generated record operating cash flow and plans to initiate a phase 3 Macy ankle clinical study, despite acknowledging uncertainties for 2026 guidance and potential variability in burn care revenue and increased operating expenses.
Vericel (VCEL) CMO sells 3,472 shares after option exercise under 10b5-1 plan
Vericel's Chief Medical Officer, Jonathan Mark Hopper, exercised stock options for 3,472 shares at $10.95 and subsequently sold those shares at $35.00 on April 2, 2026, under a pre-planned 10b5-1 trading plan. After these transactions, Hopper directly holds 75,556 common shares and 9,132 exercisable stock options. The original option grant for 135,000 shares had a vesting schedule and an expiration date of August 20, 2028.
Aberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCEL
Aberdeen Group plc increased its stake in Vericel Corporation (NASDAQ:VCEL) by 7.6% in the fourth quarter, now holding 583,884 shares valued at $21.03 million. Other institutional investors also adjusted their positions in the biotechnology company. Vericel reported strong quarterly earnings with $0.45 EPS, meeting estimates, and revenue up 23.3% year-over-year, while analysts maintain a "Moderate Buy" rating with an average price target of $56.00.
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Vericel Corporation has secured a ten-year contract worth up to $197 million with the U.S. Biomedical Advanced Research and Development Authority (BARDA). This agreement focuses on the procurement of NexoBrid for the U.S. Strategic National Stockpile, establishes a Vendor Managed Inventory system, and includes funding for the advanced development of NexoBrid, such as a next-generation formulation and a potential expanded indication for blast trauma injuries, along with the design of a U.S.-based manufacturing facility.
U.S. burn emergency stockpile gets NexoBrid in $197M BARDA pact
Vericel (NASDAQ:VCEL) has secured a ten-year contract with BARDA, valued at up to $197 million, for the procurement and advanced development of its severe burn treatment, NexoBrid. This agreement includes an initial $35 million base period, with approximately $10 million allocated for procurement and Vendor Managed Inventory (VMI) over the next 12 months, aimed at expanding the U.S. Strategic National Stockpile. The contract also covers the design of a U.S. manufacturing facility and the development of a room-temperature stable formulation and a blast trauma indication for NexoBrid.
[144] Vericel Corp SEC Filing
This article reports on a Form 144 SEC filing by Vericel Corp (VCEL) on April 2, 2026. The filing indicates a proposed sale of 3,472 shares of common stock by an individual, acquired through an option grant on August 20, 2018. The aggregate market value of the securities to be sold is $121,520.00, and the sale is expected to occur on April 2, 2026, via Fidelity Brokerage Services LLC on NASDAQ.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Vericel's (VCEL) SEC filings, including annual 10-K reports, quarterly 10-Q reports, 8-K material event reports, and insider trading forms. It details the company's financial information, business operations in advanced therapies for sports medicine and burn care, and risk factors. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing to enhance investor understanding.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for Vericel (VCEL) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details recent insider transactions and preliminary 2025 financial results, with AI-powered summaries and real-time updates to help investors understand the company's regulatory disclosures. The filings offer insights into Vericel's business in advanced therapies and associated financial performance and risks.
Soleus discloses 2.55M Vericel shares (NASDAQ: VCEL)
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 5.0% passive stake in Vericel Corp, holding 2,549,079 shares of common stock. This disclosure was made via a Schedule 13G filing with the SEC, based on Vericel's outstanding shares as of February 19, 2026. The filing indicates shared voting and dispositive power among the affiliated entities, with Guy Levy signing the joint agreement.
VCEL SEC Filings - Vericel 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Vericel's (VCEL) SEC filings, including 10-K, 10-Q, and 8-K forms, alongside Form 4 insider trading reports. It highlights recent insider transactions involving RSU vesting and grants for top executives in February 2026, as well as the company's strong 2025 financial results and 2026 revenue projections. The platform uses AI to summarize documents and analyze sentiment for investors.
Vericel corp director Hagen sells $486k in shares By Investing.com
Vericel Corp (NASDAQ:VCEL) director Heidi Hagen sold 15,000 shares for $486,149 under a pre-arranged trading plan, while also exercising options for 15,000 shares. This transaction occurred as the stock trades near its 52-week low, despite the company's strong financial health (Piotroski Score of 9) and recent positive news including strong Q4 2025 earnings, FDA approval for its new facility, and analyst price target increases.
[Form 4] Vericel Corp Insider Trading Activity
Vericel Corp director Alan L. Rubino exercised options to acquire 15,000 shares of common stock at $2.76 per share and chose to retain all of them. These options were granted in May 2016 and would have expired in May 2026. Following this transaction, Rubino directly owns 60,994 shares, and the exercised option grant is fully utilized.
Vericel corp director Hagen sells $486k in shares By Investing.com
Heidi Hagen, a director at Vericel Corp (NASDAQ:VCEL), sold 15,000 shares of common stock for $486,149 on March 23, 2026, executed under a pre-arranged trading plan. This sale occurred near the stock's 52-week low. Despite the stock sale, Vericel is considered undervalued by InvestingPro, boasts a Piotroski Score of 9, and recently reported strong Q4 2025 financial results, exceeding revenue and EPS forecasts.
